Antibody-drug conjugates (ADCs) are rapidly gaining importance as a targeted drug modality.
By combining a monoclonal antibody with a cytotoxic payload, they offer a highly specific therapeutic approach. At the same time, they introduce a new level of analytical complexity. ADCs are not single entities, but multi-component systems where each element impacts overall performance.
Key analytical considerations include:
- Drug-to-antibody ratio (DAR) and distribution
- Linker stability and payload release
- Structural heterogeneity across batches
- Functional impact on efficacy and safety
Regulatory expectations are evolving accordingly, with increasing focus on detailed characterization and a clear understanding of how structure relates to function. At AnaBioTec, analytical strategies for ADCs are designed to address this complexity, combining advanced techniques with application-driven expertise.
Download the flyer and check out what we can do for you!
